Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
blood-brain barrier
glioblastoma
immunotherapy
nanomaterial
nanotechnology
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
02
2022
accepted:
31
03
2022
entrez:
2
6
2022
pubmed:
3
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most aggressive type of brain tumor. Despite the multimodal therapies, the effectiveness of traditional treatments is not much satisfying. In recent years, immunotherapy has become the focus of tumor treatment. Unlike traditional treatments that directly target tumor cells, immunotherapy uses the body's immune system to kill tumors. However, due to the severe immunosuppressive microenvironment of GBM, it generally has a poor response to immunotherapy. In addition, the existence of the blood-brain barrier (BBB) also compromises the immunotherapeutic efficacy. Therefore, effective immunotherapy of GBM requires the therapeutic agents to not only efficiently cross the BBB but also relieve the strong immunosuppression of the tumor microenvironment of GBM. In this review, we will first introduce the CNS immune system, immunosuppressive mechanism of GBM, and current GBM immunotherapy strategies. Then, we will discuss the development of nanomaterials for GBM immunotherapy based on different strategies, roughly divided into four parts: immune checkpoint therapy, targeting tumor-associated immune cells, activating immune cells through immunogenic cell death, and combination therapy, to provide new insights for future GBM immunotherapy.
Identifiants
pubmed: 35651605
doi: 10.3389/fimmu.2022.882257
pmc: PMC9149074
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
882257Informations de copyright
Copyright © 2022 Tang, Zhang and Liu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
J Cell Mol Med. 2019 Aug;23(8):4854-4865
pubmed: 31210425
Neurology. 2021 Aug 3;97(5):218-230
pubmed: 33986138
Front Oncol. 2021 Oct 28;11:770561
pubmed: 34778089
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Bioeng Transl Med. 2020 Dec 11;6(2):e10205
pubmed: 34027092
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945
Adv Drug Deliv Rev. 2021 Dec;179:114035
pubmed: 34740765
Cancer. 2020 Jul 15;126(14):3255-3264
pubmed: 32342992
Front Immunol. 2020 Oct 21;11:544563
pubmed: 33193310
Br J Exp Pathol. 1948 Feb;29(1):58-69
pubmed: 18865105
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
ACS Nano. 2022 Jan 3;:
pubmed: 34978418
Theranostics. 2018 Nov 5;8(20):5529-5547
pubmed: 30555562
Genes (Basel). 2021 Mar 20;12(3):
pubmed: 33804731
Clin Cancer Res. 2016 Mar 1;22(5):1161-72
pubmed: 26490306
J Hematol Oncol. 2018 Mar 15;11(1):39
pubmed: 29544515
Cell Death Dis. 2020 Nov 26;11(11):1013
pubmed: 33243969
Chin Neurosurg J. 2022 Jan 19;8(1):2
pubmed: 35045874
J Control Release. 2020 Apr 10;320:63-72
pubmed: 31917294
Cancers (Basel). 2021 Feb 04;13(4):
pubmed: 33557101
Tumori. 2018 Jan-Feb;104(1):1-8
pubmed: 28967094
Pharm Res. 2019 Jul 31;36(10):140
pubmed: 31367876
J Hematol Oncol. 2018 Feb 27;11(1):31
pubmed: 29482595
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Nat Rev Neurol. 2018 Aug;14(8):482-495
pubmed: 29985475
Neurol Sci. 2017 Sep;38(9):1571-1577
pubmed: 28593528
Sci Transl Med. 2012 Apr 18;4(130):130ra46
pubmed: 22517883
Front Immunol. 2020 Oct 15;11:582106
pubmed: 33178210
Nat Neurosci. 2013 Dec;16(12):1896-905
pubmed: 24162652
Bioact Mater. 2020 May 23;5(3):694-708
pubmed: 32478203
Front Pharmacol. 2021 Nov 25;12:786700
pubmed: 34899350
ACS Nano. 2022 May 26;:
pubmed: 35616289
BMC Med. 2016 May 05;14:73
pubmed: 27151159
Front Immunol. 2021 Nov 02;12:770390
pubmed: 34795675
J Neurooncol. 2015 Jul;123(3):433-40
pubmed: 25491947
Cell. 2021 Feb 18;184(4):1000-1016.e27
pubmed: 33508229
Cold Spring Harb Perspect Biol. 2015 Jan 05;7(1):a020412
pubmed: 25561720
J Control Release. 2021 Sep 10;337:179-192
pubmed: 34274384
Acta Biomater. 2019 Mar 1;86:381-394
pubmed: 30654213
Jpn J Clin Oncol. 2021 Jan 1;51(1):3-9
pubmed: 33140101
Cell Res. 2020 Mar;30(3):229-243
pubmed: 32094452
J Clin Transl Res. 2021 Jan 20;7(1):1-21
pubmed: 34104805
N Engl J Med. 2017 Nov 16;377(20):1954-1963
pubmed: 29141164
Adv Mater. 2021 Jun;33(22):e2008802
pubmed: 33893670
Biomaterials. 2016 Jul;96:47-62
pubmed: 27135716
Front Pharmacol. 2021 May 06;12:681320
pubmed: 34025438
Adv Sci (Weinh). 2021 Sep;8(17):e2004381
pubmed: 34196474
Elife. 2020 Feb 04;9:
pubmed: 32014107
Nature. 2015 Jul 16;523(7560):337-41
pubmed: 26030524
Cell Mol Immunol. 2019 Jan;16(1):28-39
pubmed: 30002451
Curr Urol Rep. 2018 Nov 7;19(12):109
pubmed: 30406502
Chem Sci. 2018 Jan 31;9(10):2674-2689
pubmed: 29732051
J Control Release. 2017 Dec 28;268:128-146
pubmed: 29051064
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Int J Nanomedicine. 2019 May 02;14:3203-3220
pubmed: 31118632
J Control Release. 2016 Dec 28;244(Pt A):14-23
pubmed: 27825958
Biomater Sci. 2020 Sep 7;8(17):4653-4664
pubmed: 32672255
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Cancer Immunol Immunother. 2016 Nov;65(11):1339-1352
pubmed: 27576783
Nat Commun. 2019 Aug 28;10(1):3850
pubmed: 31462642
J Nanobiotechnology. 2020 Feb 17;18(1):31
pubmed: 32066449
ACS Nano. 2019 Feb 26;13(2):1365-1384
pubmed: 30721028
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396284
Pharmaceutics. 2021 Oct 12;13(10):
pubmed: 34683961
Neuro Oncol. 2012 Aug;14(8):958-78
pubmed: 22573310
Biomacromolecules. 2020 Dec 14;21(12):5148-5161
pubmed: 33112134
Theranostics. 2020 Jan 1;10(3):1355-1372
pubmed: 31938069